Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Omigapil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 7/20 | 0.40 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omigapil SCHEMBL5953608 | 1.00 | PYCR1 (0.40) | PYCR1MAOAMAOBLMNAUSP2 | |
| Omigapil SCHEMBL29369408 | 1.00 | PYCR1 (0.40) | PYCR1MAOAMAOBLMNAUSP2 | |
| Omigapil SCHEMBL978230 | 1.00 | PYCR1 (0.40) | PYCR1MAOAMAOBLMNAUSP2 | |
| Omigapil SCHEMBL5953610 | 1.00 | PYCR1 (0.40) | PYCR1MAOAMAOBLMNAUSP2 | |
| Omigapil SCHEMBL29377962 | 0.90 | PYCR1 (0.45) | PYCR1MAOAMAOBLMNAUSP2 | |
| Omigapil SCHEMBL333032 | 0.90 | PYCR1 (0.45) | PYCR1MAOAMAOBLMNAUSP2 | |
| Fumaric Acid SCHEMBL8892596 | 0.89 | KDM4E (0.36) | LMNAALDH1A1KDM4EHPGDDRD2 | |
| Maleic Acid SCHEMBL8892159 | 0.85 | NPC1 (0.40) | MAOBLMNAALDH1A1BLMKDM4E | |
| SCHEMBL5953640 | 0.78 | PYCR1 (0.45) | PYCR1MAOAMAOBLMNAUSP2 | |
| SCHEMBL8890871 | 0.78 | DRD2 (0.41) | MAOBLMNACYP3A4DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004176-B1 | USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY | SANTHERA PHARMACEUTICALS CH (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-7999002-B2 | Use of N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) or a pharmaceutically acceptable addition salt thereof for the prophylaxis and/or treatment of muscular dystrophy | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-08-16 | — | — | US | disclosed |
| US-7875648-B2 | for congenital muscular dystrophy or myopathy resulting from mutations in any of the collagen VI genes selected from the group consisting of Col6A1, Col6A2, and Col6A3; administered orally; normalizes the pathological changes at the ultrastructural level in mitochondria of muscle tissue | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-01-25 | — | — | US | disclosed |
| EP-1924255-B1 | USE OF N-(DIBENZ (B,F)OXEPIN-10-YLMETHYL)-N-METHYL-N-PROP-2-YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND/OR TREATMENT OF MUSCULAR DYSTROPHY | SANTHERA PHARMACEUTICALS CH (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20100160269-A1 | Use of N-(dibenz(B,F)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine or a pharmaceutically acceptable addition salt thereof for the prophylaxis and/or treatment of muscular dystrophy | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-06-24 | — | — | US | disclosed |
| US-20090176867-A1 | USE OF N-(DIBENZ(B,F)OXEPIN-10-YLMETHYL)-N-METHYL-N-PROP-2-YNYLAMINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT THEREOF FOR THE PROPHYLAXIS AND/OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-07-09 | — | — | US | disclosed |
| EP-2004176-A1 | USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| EP-1924255-A1 | USE OF N-(DIBENZ (B,F)OXEPIN-10-YLMETHYL)-N-METHYL-N-PROP-2-YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND/OR TREATMENT OF MUSCULAR DYSTROPHY | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007115776-A1 | USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| EP-1842539-A1 | Use of N- (dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007022951-A1 | USE OF N-(DIBENZ (B,F)OXEPIN-10-YLMETHYL)-N-METHYL-N-PROP-2-YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND/OR TREATMENT OF MUSCULAR DYSTROPHY | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| EP-1757284-A1 | Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176867-A1 | USE OF N-(DIBENZ(B,F)OXEPIN-10-YLMETHYL)-N-METHYL-N-PROP-2-YNYLAMINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT THEREOF FOR THE PROPHYLAXIS AND/OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY | MYOF, COL14A1, COL2A1 | DRD2 1305/4885PYCR1 1650/4885MAOA 611/4885 |
| US-20100160269-A1 | Use of N-(dibenz(B,F)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine or a pharmaceutically acceptable addition salt thereof for the prophylaxis and/or treatment of muscular dystrophy | SMN1; SMN2, MYOF, MBNL1 | DRD2 668/4885PYCR1 3468/4885MAOA 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.